Maju Mathews, MD

chief medical officer

Maju Mathews, MD, is a Board Certified Psychiatrist with over 13 years of neuroscience drug development experience focused on Psychiatric drugs. He most recently held the position of Senior Global Medical Affairs Leader for Neuropsychiatry at Janssen Pharmaceuticals.

Maju has worked on over 12 different compounds across multiple psychiatric conditions, most recently contributing to the development and approval of esketamine (SPRAVATO®) for Treatment Resistant Depression and Suicidality. Prior to joining Janssen, he held roles of increasing responsibilities at Forest Labs and Indivior, overseeing the development of programs in major depression, generalized anxiety disorder, bipolar mania, bipolar depression, schizophrenia, substance misuse, and a number of pediatric programs. Before entering the pharmaceutical industry, Maju was a Senior Medical Officer Reviewer at the US FDA for 3 years, where he was responsible for a number of NDA, IND and safety reviews. 

His broad experience in research, medical affairs, regulatory, & market access and as a practicing clinician, brings extensive knowhow to the perception Neuroscience team, where he will be responsible for all aspects of the clinical, medical and regulatory strategy and clinical development of the company's assets.  Maju continues to be active clinically part time and provides care to patients with a focus on mood disorders and ADD.